Ebola 2026 — June 9 Update: 550 Cases, 101 Deaths, What Changed in 9 Days

What Has Changed — The Key Developments Since May 31

When we last published a full data update on May 31, the DRC had 282 confirmed cases and approximately 18 confirmed deaths. Nine days later, both numbers have changed substantially. The case count has nearly doubled. Deaths have increased more than fivefold in confirmed figures as laboratory confirmation has accelerated. And the geographic picture has shifted in ways that matter clinically and epidemiologically.

Three developments stand out:

Geographic expansion within the DRC. While Ituri Province remains the epicenter — accounting for 518 of the 550 confirmed cases — the outbreak has now been confirmed in North Kivu (29 cases across 7 health zones) and South Kivu (3 cases). This is a different situation than a single-province outbreak. North Kivu includes Goma, the largest city in eastern DRC and a major transit hub. The presence of confirmed cases there represents a meaningful escalation in spread risk.

Uganda's expansion to Kampala. Uganda's case count has grown from 9 to 19, and cases have been confirmed in Kampala — the country's capital, with 3.6 million residents. Urban cases in a capital city are qualitatively different from border-area cases. They represent a larger susceptible population, greater healthcare system exposure, and higher international travel connectivity.

Pace of acceleration. Thirty-five new confirmed cases in 24 hours — reported by the ECDC on June 9 — suggests the outbreak is still in its acceleration phase, not stabilizing. That single metric is currently the most closely watched indicator in the global public health community.

Geographic Distribution — By the Numbers

Understanding the Death Rate — What 17.4% Actually Means

The current case fatality rate — approximately 17.4 percent — is lower than the historical CFR of previous Bundibugyo outbreaks, which ranged from 25 to 50 percent. This requires careful interpretation rather than straightforward reassurance.

As laboratory testing capacity improves and becomes more accessible in affected areas, more cases are being confirmed — including milder presentations that might not have been captured in earlier, more limited testing environments. Adding milder cases to the denominator mathematically lowers the percentage rate even as the absolute number of deaths rises. The number of deaths is rising. One hundred and one confirmed deaths as of today, compared to 18 at our last full count.

Seventeen recoveries have been confirmed from Bundibugyo virus disease as of this report. That is clinically meaningful — it demonstrates that the immune system can clear this infection, even without specific antivirals or monoclonal antibody treatments. Understanding what characterizes survivors versus non-survivors is one of the key clinical research questions now being investigated in field settings.

The International Response — What Is Being Done

The scale of international engagement has increased substantially since our last update. On June 5, the Africa Centres for Disease Control and Prevention and the World Health Organization jointly launched a continental preparedness and response plan — requesting US$518 million to support African countries in detecting, containing, and managing the outbreak.

Bilateral funding has been committed: the United Kingdom pledged up to £20 million, the United States announced $112 million in assistance covering PPE, contact tracing, and diagnostics, and the European Union pledged €15 million. MSF is building a 65-bed Ebola treatment centre in Ituri Province, Bunia. The WHO has deployed additional clinical and epidemiological support to both DRC and Uganda.

On the vaccine front: the WHO formally recommended on May 28 against the use of rVSV-ZEBOV (Ervebo) — the vaccine that successfully supported the response to the 2018–2020 DRC Zaire ebolavirus outbreak — for this Bundibugyo outbreak. Evidence for cross-species protection is insufficient. This is the most significant gap in the current response toolkit.

CEPI announced on June 1 that it is fast-tracking funding for three vaccine candidates specifically targeting Bundibugyo ebolavirus. These are not yet deployable — they are in early-stage development pipelines — but the acceleration of that process is the most important medium-term development in outbreak control capacity.

Outside Africa — What the Global Risk Picture Looks Like

As of June 9, 2026, there are no confirmed Ebola cases outside the DRC and Uganda. Brazil's two cases — which generated significant international attention in late May — were officially ruled out on June 1: the São Paulo patient was diagnosed with meningococcal meningitis; the Rio de Janeiro patient with malaria. Both cases demonstrated that national surveillance systems are functioning and that the clinical differential diagnosis protocol is being applied correctly.

The CDC maintains a Level 3 Travel Health Notice for the DRC (avoid non-essential travel) and a Level 1 Notice for Uganda (practice enhanced precautions). European countries' health authorities, through ECDC coordination, are maintaining heightened awareness at entry points and within healthcare systems for travelers from affected regions.

Why It Is Spreading — The Context That Matters

The speed of this outbreak's spread does not reflect any change in the biological transmission properties of Bundibugyo virus. It reflects the conditions in which the virus is operating. Eastern DRC is one of the world's most complex active humanitarian emergencies. The M23 armed movement controls parts of North Kivu. Population displacement — from conflict, from mining activity, from cross-border trade — creates the conditions in which disease containment is genuinely hard to achieve even when the clinical and epidemiological protocols are correct.

The WHO has consistently emphasized that community engagement — building trust with affected communities so that people report illness, cooperate with contact tracing, and understand the protocols for managing a possible Ebola exposure — is the single most important determinant of whether this outbreak is brought under control. That is not a diplomatic observation. It is an epidemiological one: contact tracing only works when contacts can be found and will engage with health teams.

What to Watch — The Three Key Indicators

1. Daily case trend. The most important near-term indicator is not the cumulative total — it is whether new daily confirmed cases are rising, plateau-ing, or declining. Thirty-five new confirmed cases in 24 hours reflects an outbreak still in acceleration. A sustained decline in daily incidence would signal that contact tracing and isolation are beginning to break transmission chains.

2. Geographic spread. Continued confirmation of cases in Kampala — or first confirmation of cases in a new country — would represent a significant escalation. Urban spread in a major capital city would require a fundamentally different response scale and approach than a geographically concentrated outbreak in rural Ituri. As of today, this threshold has not been crossed.

3. Vaccine pipeline. If any of the three CEPI-funded Bundibugyo vaccine candidates reaches emergency use authorization — even in a compressed accelerated timeline — the response options change substantially. Ring vaccination, which helped contain the 2018–2020 DRC outbreak, requires an effective vaccine. Without one, containment depends entirely on case isolation and contact tracing in some of the most challenging operational environments in the world.